Pills at a Price

Biopharma is Indian pharma’s next frontier. It is also its Achilles’ heel

When India’s largest drugmaker chooses to go with a Korean contract manufacturer, it’s a sign of changing times. Then, separately, comes the government with $250 million saying it wants to help. And how?

overcoming-2127669_1280.png

As far as sobriquets go, nothing can be nobler than the ‘pharmacy of the world’. Indian pharmaceutical companies have earned it. They supply 40% of the $70 billion generics market in the US, though it’s another matter that their dominance is under stress today. Their oversight on quality has come to pass and in spades. So, when India’s largest drug company, Sun Pharma, said last week that it had inked a long-term partnership with Samsung Biologics to manufacture its new drug, it signalled a shift. Manufacturing prowess of the past may not be enough for the drugs…

To access this content, you must purchase Quarterly, or log in if you are a member.

Sign up to read this story for free right now

Stories on The Ken are available only for its subscribers. Join us now to get instant access.

Have an account?

Related stories

More stories in /Analysis & /Healthcare

See all in Analysis & Healthcare

This story is exclusively for premium subscribers. Subscribe now to get access.

Read the full story now. Subscribe to The Ken

Why should I pay for reading your stories?

Lots of effort We go to lengths to put in time and resources required to get the most factual, honest stories out there.

Advertising independent Our primary allegiance will always be to our readers. We won't be swayed by our advertisers and investors.

We can't do all of this by giving away our journalism for free and selling our readers by the thousands to advertisers.

Get premium access